The efficiency of rifaximin in the correction of the small intestinal bacterial overgrowth syndrome in chronic inflammatory bowel diseases and functional bowel disorders

The efficiency of rifaximin in the correction of the small intestinal bacterial overgrowth syndrome in chronic inflammatory bowel diseases and functional bowel disorders

Background. The article deals with the problem of small intestinal bacterial overgrowth (SIBO) syndrome in patients with chronic inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), and ways to correct it. The purpose was to determine the incidence of SIBO in Crohn’s disease (CD), u...

Full description

Bibliographic Details
Main Authors:	Yu.M. Stepanov, N.S. Fedorova, E.V. Zyhalo
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2019-11-01
Series:	Gastroenterologìa
Subjects:	ulcerative colitis crohn’s disease irritable bowel syndrome small intestinal bacterial overgrowth syndrome rifaximin
Online Access:	http://gastro.zaslavsky.com.ua/article/view/182740

Similar Items

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
by: Xiaojun Zhuang, et al.
Published: (2020-06-01)

Use of Rifaximin in Irritable Bowel Syndrome Treatment
by: Hubert Wróblewski, et al.
Published: (2021-08-01)

Efficacy of rifaximine in intestinal bacterial overgrowth syndrome in patients after cholecystectomy
by: Tat'yana Anatol'evna Mechetina, et al.
Published: (2011-12-01)

Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome
by: Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer
Published: (2021-12-01)

Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients
by: J.S. Lasa, et al.
Published: (2015-04-01)

Advances in Therapy for Irritable Bowel Syndrome with Diarrhea: Role of Rifaximin in Combination with Metronidazole
by: Arif A Faruqui
Published: (2024-01-01)

Impact of Small Intestinal Bacterial Overgrowth in Patients with Inflammatory Bowel Disease and Other Gastrointestinal Disorders—A Retrospective Analysis in a Tertiary Single Center and Review of the Literature
by: Julia Wanzl, et al.
Published: (2023-01-01)

Rational Use of Antibiotics in the Treatment of Functional Bowel Disorders
by: Roberta Fasulo, et al.
Published: (2010-07-01)

Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update
by: Will Takakura, et al.
Published: (2020-07-01)

Small Intestinal Bacterial Overgrowth: A Case-Based Review
by: Kristen H. Reynolds
Published: (2015-11-01)

Irritable Bowel and Bacterial Overgrowth Syndromes: a Bacterial Link Hypothesis of Functional Disease
by: K. V. Ivashkin, et al.
Published: (2021-04-01)

Serotonin Pathway of Tryptophan Metabolism in Small Intestinal Bacterial Overgrowth—A Pilot Study with Patients Diagnosed with Lactulose Hydrogen Breath Test and Treated with Rifaximin
by: Cezary Chojnacki, et al.
Published: (2021-05-01)

The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders
by: Giuseppe Losurdo, et al.
Published: (2020-05-01)

Diagnostic Implications of Irritable Bowel Syndrome Is an Independent Risk Factor for Undergoing Surgical Interventions in Patients with Inflammatory Bowel Disease
by: Yuhan Fu, et al.
Published: (2023-05-01)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
by: Xiaojun Zhuang, et al.
Published: (2018-07-01)

Small Intestinal Bacterial Overgrowth (SIBO): Result of Altered Defensive Mechanism in Gastrointestinal – A Review
by: Alvin Hartanto Kurniawan, et al.
Published: (2020-07-01)

Diagnosis and treatment of small intestinal bacterial overgrowth
by: Karolina Zadrozna, et al.
Published: (2022-11-01)

Prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome (IBS): Correlating H2 or CH4 production with severity of IBS
by: Philippe Onana Ndong, et al.
Published: (2023-04-01)

Treatment of small intestinal bacterial overgrowth: Conventional antibiotic therapy and alternative therapy - probiotics and low FODMAP diet
by: Maria Litwiniuk, et al.
Published: (2023-06-01)

Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome
by: Porter Chad K, et al.
Published: (2012-05-01)

Antimicrobial treatment improves tryptophan metabolism and mood of patients with small intestinal bacterial overgrowth
by: Cezary Chojnacki, et al.
Published: (2022-09-01)

Irritable Bowel Syndrome Is an Independent Risk Factor for Developing Opioid Use Disorder in Patients with Inflammatory Bowel Disease
by: Yuhan Fu, et al.
Published: (2023-05-01)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
by: Enzo Vicari, et al.
Published: (2014-10-01)

Clinical experience with the use of the intestinal antibiotic Rifaximin for celiac disease
by: L. S. Оrеshkо, et al.
Published: (2019-10-01)

Small intestinal bacterial overgrowth as a cause of lactase deficiency
by: N A Fadeeva, et al.
Published: (2015-02-01)

Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Irritable Bowel Syndrome who Have Suffered COVID-19
by: A. V. Nalyotov, et al.
Published: (2022-09-01)

Comparison of abdominal bloating severity between irritable bowel syndrome patients with high and low levels of breath hydrogen excretion in a lactulose breath test
by: J. Lasa, et al.
Published: (2012-04-01)

Practical Recommendation of the Scientific Сommunity for Human Microbiome Research (CHMR) and the Russian Gastroenterological Association (RGA) on Small Intestinal Bacterial Overgrowth in Adults
by: V. T. Ivashkin, et al.
Published: (2022-09-01)

(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review
by: Marilyn Hagan, et al.
Published: (2021-03-01)

Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome
by: Tomasz Wollny, et al.
Published: (2021-11-01)

Age peculiarities of intestinal microbiocenosis disorders in the patients with ulcerative colitis and Crohn’s disease
by: Yu.M. Stepanov, et al.
Published: (2020-10-01)

Comparative efficacy of <i>Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus</i> composition and prucalopride in treatment of constipation variant of irritable bowel syndrome
by: V. T. Ivashkin, et al.
Published: (2024-03-01)

Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico
by: O. Novoa-Farías, et al.
Published: (2016-01-01)

Comparative assessment of <i>Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus</i> and <i>Saccharomyces boulardii</i> efficacy at diarrheal variant of irritable bowel syndrome
by: V. T. Ivashkin, et al.
Published: (2024-03-01)

Infrequent small bowel intestinal bacterial overgrowth in malnourished Zambian children
by: Namwiinga Ndulo, et al.
Published: (2020-02-01)

Small Bowel Bacterial Overgrowth Syndrome in Patients with Bronchial Asthma
by: N. D. Potskhverashvili, et al.
Published: (2018-09-01)

Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study
by: Keszthelyi Daniel, et al.
Published: (2012-09-01)

Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study)
by: Huaizhu Guo, et al.
Published: (2023-02-01)

Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review
by: David Avelar Rodriguez, et al.
Published: (2019-09-01)

Low FODMAP Diet for Functional Gastrointestinal Symptoms in Quiescent Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials
by: Maria G. Grammatikopoulou, et al.
Published: (2020-11-01)